AbCellera Biologics Inc. (ABCL) KPIs and segments
Close on Nov 18, 2026Market cap $3.38BP/E –Yield –
KPIs & segments
Operating metrics and segments that drive AbCellera Biologics's business
AbCellera Biologics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Research fees($M) | 3.90 | 8.12 | 7.68 | 8.82 | 6.64 | 4.07 | 4.77 | 6.29 | 5.45 | 9.77 | 8.74 | 6.41 | |
Milestone payments($M) | 1 | 0 | 0 | 0 | 0 | 1.50 | 0 | 0.25 | 0 | ||||
Licensing and royalty revenue($M) | 0.15 | 0.19 | 36.2 | 0.14 | 10.4 | 0.17 | 0.28 | 0.22 | 0.37 | 0.18 | 0.19 | 0.19 | |
Earlier reporting (last reported 2024)1 | |||||||||||||
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-08-05.
See a number that looks wrong?